Academic Journals Database
Disseminating quality controlled scientific knowledge

Neoadjuvant Chemotherapy in Esophageal Cancer: Single Institution Experience

Author(s): Hany Eldeeb | Waleed Abozeed | David Hunter | Shaffi Shaikh

Journal: Middle East Journal of Cancer
ISSN 2008-6709

Volume: 2;
Issue: 3 ;
Start page: 105;
Date: 2011;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: Neoadjuvant chemotherapy | Esophageal cancer | Surgery

Background: Esophageal cancer is a major clinical problem that has a generally poor prognosis. As a result, there has been interest in combining surgery with neoadjuvant chemotherapy in an attempt to improve clinical outcomes. Evidence for clinical benefit from preoperative chemotherapy exists but it is not clear which patients(stage, tumor location, and histology) will benefit the most from this preoperative treatment.Methods: This study retrospectively analyzed the outcome of 71 patients with operable esophageal carcinoma treated at Northamptonshire Oncology Centre, UK from January 2001 until July 2008. Patients were treated with two cycles of neoadjuvant chemotherapy followed by surgery. Data were analyzed by Kaplan-Meier plots, Cox regression modeling and chi-squared test.Results:Median patient’s age was 64 years. Male patients represented 83% of the cases. Of patients, 63% had an ECOG performance status of 1. Surgical resection was done for 63 (88.7%) patients. Two year overall survival in this cohort was 5.6%. Univariate analysis identified only surgical resection to be associated with betterprognosis (P
RPA Switzerland

RPA Switzerland

Robotic process automation


Tango Rapperswil
Tango Rapperswil